[VIRTUAL] ENPAC: Phase II trial with safety lead of enzalutamide in combination with paclitaxel and carboplatin for advanced or recurrent endometrioid endometrial adenocarcinoma

[VIRTUAL] Maintenance olaparib for patients with newly diagnosed, advanced ovarian cancer and a BRCA mutation: 5-year follow-up from SOLO1

[VIRTUAL] A proof of concept randomized phase 2 non-inferiority trial on simple versus modified radical hysterectomy in IA2-IB1 cervical cancer ≤ 2cm (LESSER)

[VIRTUAL] Randomized phase II trial of durvalumab (anti-PDL1) and tremelimumab (anti-CTLA4) administered in combination versus sequentially for the treatment of recurrent platinum-resistant non-clear cell ovarian cancer (NCT03026062)

[VIRTUAL] An open-label phase II study of dostarlimab (TSR-042), bevacizumab (bev), and niraparib combination in patients (pts) with platinum-resistant ovarian cancer (PROC): Cohort A of the OPAL trial

[VIRTUAL] Pembrolizumab treatment of advanced cervical cancer: Updated results from the phase II KEYNOTE-158 study

[VIRTUAL] A multicenter, open-label, randomized, phase III study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab versus treatment of physician’s choice in patients with advanced endometrial cancer

[VIRTUAL] Homologous recombination repair mutation gene panels (excluding BRCA) are not predictive of maintenance olaparib plus bevacizumab efficacy in the first-line PAOLA-1/ENGOT-ov25 trial

[VIRTUAL] Genomic profiling of advanced cervical cancer to predict response to PD-1 inhibitor combination therapy: A secondary analysis of the CLAP trial

[VIRTUAL] Efficacy of niraparib by timing of surgery and residual disease: A post-hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study

[VIRTUAL] Association of BRCA1/2, homologous recombination deficiency, and PD-L1 with clinical outcomes in patients receiving atezolizumab versus placebo combined with carboplatin, paclitaxel, and bevacizumab for newly diagnosed ovarian cancer: Explor

[VIRTUAL] Apatinib combined with pegylated liposomal doxorubicin (PLD) versus PLD for platinum-resistant recurrent ovarian cancer (APPROVE): A multicenter, randomized, controlled, open-label, phase II trial

[VIRTUAL] Long-term safety and secondary efficacy endpoints in the ENGOT-OV16/NOVA phase III trial of niraparib in recurrent ovarian cancer

[VIRTUAL] Rucaparib versus chemotherapy in patients with advanced, relapsed ovarian cancer and a deleterious BRCA mutation: Efficacy and safety from ARIEL4, a randomized phase III study

[VIRTUAL] Patients with recurrent gynecologic cancers and Wnt activating mutations demonstrated greater clinical benefit when treated with DKN-01 therapy